ES2928395T3 - Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados - Google Patents

Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados Download PDF

Info

Publication number
ES2928395T3
ES2928395T3 ES21720509T ES21720509T ES2928395T3 ES 2928395 T3 ES2928395 T3 ES 2928395T3 ES 21720509 T ES21720509 T ES 21720509T ES 21720509 T ES21720509 T ES 21720509T ES 2928395 T3 ES2928395 T3 ES 2928395T3
Authority
ES
Spain
Prior art keywords
compound
dimethyltryptamine
deuterated
formula
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21720509T
Other languages
English (en)
Spanish (es)
Inventor
Peter Rands
Tiffanie Benway
Zelah Joel
Marie Layzell
Ellen James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Small Pharma Ltd
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Priority claimed from GBGB2018950.2A external-priority patent/GB202018950D0/en
Priority claimed from US17/108,679 external-priority patent/US20220168274A1/en
Priority claimed from GBGB2018955.1A external-priority patent/GB202018955D0/en
Priority claimed from US17/108,938 external-priority patent/US20220169606A1/en
Priority claimed from GB2103981.3A external-priority patent/GB2605144A/en
Priority claimed from US17/208,583 external-priority patent/US11773062B2/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Priority claimed from PCT/EP2021/060750 external-priority patent/WO2021116503A2/en
Publication of ES2928395T3 publication Critical patent/ES2928395T3/es
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
ES21720509T 2020-06-02 2021-04-23 Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados Active ES2928395T3 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
US16/890,664 US11771681B2 (en) 2019-06-03 2020-06-02 Therapeutic compounds
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US17/108,679 US20220168274A1 (en) 2020-12-01 2020-12-01 Parenteral Formulation
GBGB2018955.1A GB202018955D0 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GBGB2018950.2A GB202018950D0 (en) 2020-12-01 2020-12-01 Parenteral formulation
US17/108,938 US20220169606A1 (en) 2020-12-01 2020-12-01 Compositions and compounds for bioanalysis
GB2103981.3A GB2605144A (en) 2021-03-22 2021-03-22 Deuterated compounds
US17/208,583 US11773062B2 (en) 2021-03-22 2021-03-22 Deuterated compounds
PCT/EP2021/060750 WO2021116503A2 (en) 2020-06-02 2021-04-23 Deuterated compounds

Publications (1)

Publication Number Publication Date
ES2928395T3 true ES2928395T3 (es) 2022-11-17

Family

ID=84083617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21720509T Active ES2928395T3 (es) 2020-06-02 2021-04-23 Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados

Country Status (10)

Country Link
JP (1) JP7288154B2 (pl)
KR (1) KR102589605B1 (pl)
CN (1) CN116056763B (pl)
AU (1) AU2021204158B2 (pl)
CA (1) CA3179161C (pl)
ES (1) ES2928395T3 (pl)
IL (1) IL298541B1 (pl)
MX (1) MX2022014900A (pl)
NZ (1) NZ794833A (pl)
PL (1) PL3902541T3 (pl)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103189A1 (en) * 2006-10-19 2008-05-01 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted indoles
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
PL3844147T3 (pl) * 2019-11-07 2022-07-18 Small Pharma Ltd Związki chemiczne

Also Published As

Publication number Publication date
AU2021204158A1 (en) 2023-01-05
JP7288154B2 (ja) 2023-06-06
NZ794833A (en) 2023-03-31
JP2023520256A (ja) 2023-05-16
CA3179161C (en) 2023-10-31
PL3902541T3 (pl) 2022-11-14
CA3179161A1 (en) 2021-06-17
CN116056763A (zh) 2023-05-02
CN116056763B (zh) 2024-03-05
KR102589605B1 (ko) 2023-10-13
KR20230007547A (ko) 2023-01-12
IL298541B1 (en) 2024-04-01
MX2022014900A (es) 2023-03-27
IL298541A (en) 2023-01-01
AU2021204158B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
ES2920681T3 (es) Compuestos
EP3902541B1 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11471417B2 (en) Deuterated N,N-dimethyltryptamine compounds
ES2922101T3 (es) Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados
ES2938859T3 (es) Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
BR112020014151A2 (pt) Compostos de benzamida
CN103492370A (zh) 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
JP2019535643A (ja) （ｒ）−２−アミノ−３−フェニルプロピルカルバメートの溶媒和物フォーム
TW202237565A (zh) 氘化化合物
US20230181530A1 (en) Deuterated or partially deuterated n,n-dimethyltryptamine compounds
ES2928395T3 (es) Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados
WO2023023474A1 (en) Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
GB2605144A (en) Deuterated compounds